Korea's ViroMed Starts Trial of Gene Therapy for Diabetic Foot Ulcers

ViroMed of South Korea has begun dosing patients in a US Phase III trial of VM202, a gene therapy drug, in patients with non-healing diabetic foot ulcers and concomitant peripheral artery disease. Earlier this year, ViroMed filed in China to start a Phase III trial of VM202 in patients with critical limb ischemia, an advanced state of peripheral artery disease. When injected into muscles, VM202 is intended to induce new microvasculature and alleviate a number of conditions associated with diabetes and loss of peripheral arteries. More details.... Stock Symbol: (KOSDAQ: 084990) Share this with colleagues: // //